[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 4 sources · 3 days · First seen · Last updated

Cybin clinical and organizational development

Overview

Cybin, also known as Helus Pharma, is advancing its psychedelic-based therapeutic pipeline while undergoing leadership changes. The company recently appointed Michael Halstead as CEO, Regina Donohue as Chief People Officer, and Suresh Durgam to its Scientific Advisory Board.

On the clinical front, the company is prioritizing its Phase 3 APPROACH study for HLP003, a deuterated psilocybin for Major Depressive Disorder, noting that patient recruitment was completed ahead of schedule. The pipeline also includes HLP004, a deuterated DMT preparation for anxiety disorders.

Financial analysts have responded positively to these developments. TD Cowen significantly raised its price target for the company from $8.00 to $62.00, citing clearer timing for late-stage data on the lead drug, new leadership, and positive sector trends. Topline results for the HLP003 study are expected in mid-November 2026. Additionally, Millennium Management LLC has notably increased its stake in the company.

Entities

Michael Halstead · Regina Donohue · Wells Fargo & Company · Wells Fargo · Cybin Inc.

Timeline

  1. 3 days ago

    [BUSINESS] 2 sources
    Cybin Inc. receives 'Buy' ratings and significant price target hike

    Cybin Inc. shares saw positive momentum after TD Cowen raised its price target to $62. The biotech firm is advancing late-stage trials for psychedelic-based neuropsychiatry treatments.

  2. 6 days ago

    [BUSINESS] 2 sources
    Cybin advances clinical pipeline and leadership team

    Cybin is strengthening its leadership and scientific advisory board while advancing Phase 3 clinical trials for its psychedelic-based mental health treatments, including HLP003 for depression.

Sources

ad-hoc-news.de · kapitalmarktexperten.de · mommygearest.com · newsable.asianetnews.com